BDPT is an OTC-listed biotech firm developing sustainable bio-materials with a positive cash balance despite substantial operating losses and zero revenue in the last three years.
An investor might buy BDPT as a speculative turnaround play if the company can successfully commercialize its bio-materials, potentially turning the current cash reserves into substantial market cap upon IPO or acquisition. The clean balance sheet with no long-term liabilities and a positive working capital position offers a safety net that many distressed biotech firms lack, providing room for strategic pivots.
The bear case is overwhelming given three consecutive years of zero revenue and a massive operating loss that erodes shareholder equity by nearly $900k annually. With a retained earnings deficit exceeding $9 million and no current product sales, the company faces an imminent risk of bankruptcy unless it secures drastic new capital or achieves a breakthrough in its technology pipeline.
BIOADAPTIVES, INC. (BDPT) is a biotechnology company focused on developing next-generation bio-based materials and sustainable solutions for commercial applications. The firm operates in the specialized chemical and industrial materials sectors, targeting markets that demand high-performance, environmentally friendly alternatives to traditional polymers. Despite recent financial reporting showing significant net losses, the company maintains a strong cash position relative to its current liabilities to fund ongoing R&D.
Management has successfully preserved liquidity with a positive net change in cash of $76k and substantial cash on hand, though this masks the severe operational inefficiency where operating losses of $905k dwarf the tiny revenue base. The company is burning through capital at a rate that exceeds its current financing inflows from preferred shares, signaling an urgent need for either a major milestone in product development or significant equity/debt financing to avoid insolvency.
The bio-based materials industry is growing rapidly as regulations push for sustainability, offering high barriers to entry that protect established players but leave early-stage entrants vulnerable to cash flow crises. Companies in this space typically require years of R&D investment before reaching profitability, making the current financial state of BDPT a common but dangerous feature of the sector's lifecycle.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $17.2K | $28.6K | $12.7K |
| Cost of Revenue | $10.1K | $17.7K | $8.6K |
| Gross Profit | $7.1K | $10.8K | $4.0K |
| Operating Expenses | $429.0K | $239.7K | $606.1K |
| Operating Income | $-421.9K | $-228.9K | $-602.1K |
| G&A | $254.1K | $101.5K | $335.3K |
| Stock-Based Comp | $0 | — | — |
| Amortization | $62.1K | $28.2K | $19.9K |
| Other OpEx | $174.9K | $138.3K | $270.8K |
| Non-Operating Income | $-473.7K | $0 | $0 |
| Interest Expense | $289.1K | $162.9K | $92.0K |
| Pre-Tax Income | $-895.6K | $-228.9K | $-602.1K |
| Income Tax | $0 | $483.5K | $302.7K |
| Continuing Ops | $-895.6K | $-712.5K | $-904.8K |
| Discontinued Ops | $0 | $0 | $5.6K |
| Net Income | $-895.6K | $-712.5K | $-899.2K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-895.6K | $-712.5K | $-899.2K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $34.3K | $88.6K | $261.9K |
| Cash & Equivalents | $25.4K | $60.8K | $261.9K |
| Marketable Securities | $42 | $0 | $0 |
| Inventory | $8.9K | $15.3K | $19.1K |
| Other Current Assets | $0 | $12.5K | $-19.1K |
| Long-Term Assets | $3.0K | $15.4K | $0 |
| Intangibles | — | $15.2K | — |
| Other LT Assets | — | $275 | — |
| Total Assets | $37.3K | $104.0K | $261.9K |
| Current Liabilities | $1.5M | $1.8M | $1.7M |
| Accounts Payable | $6.9K | — | — |
| Other Current Liab | $1.5M | $1.6M | — |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $1.5M | $1.8M | $1.7M |
| Shareholders' Equity | $-1.5M | $-1.6M | $-1.5M |
| Paid-In Capital | $6.1M | $6.5M | $7.7M |
| Retained Earnings | $-7.6M | $-8.3M | $-9.2M |
| Total L&E | $37.3K | $104.0K | $261.9K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-895.6K | $-712.5K | $-899.2K |
| Non-Cash Adjustments | $479.6K | $435.6K | $604.8K |
| Working Capital Changes | $188.7K | $53.1K | $44.8K |
| Cash from Operations | $-227.3K | $-223.8K | $-249.5K |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $169.7K | $259.1K | $326.2K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-57.5K | $35.4K | $76.7K |
| Beginning Cash | $82.9K | $25.4K | $60.8K |
| Ending Cash | $25.4K | $60.8K | $137.5K |
The company's financial profile suggests operations are currently concentrated in research and development and strategic partnerships, as evidenced by high general and administrative expenses ($335k) with negligible revenue ($12.7k). The lack of long-term assets and inventory indicates a pre-revenue or early-stage clinical/product development phase where value is derived from intellectual property and future commercialization potential rather than current sales.
1. Persistent net losses of nearly $900k annually indicate an unsustainable burn rate without significant revenue growth. 2. Zero revenue for the last three years (2022-2024) creates high uncertainty regarding commercial viability and product-market fit. 3. Significant accumulated retained earnings deficit of $9.2M suggests a long history of profitability challenges. 4. Operating expenses of $606k far exceed gross profits, highlighting an inability to cover costs with current operations.
1. Potential proprietary bio-based technology that could disrupt traditional material markets with lower environmental impact. 2. A healthy cash reserve of $261k providing runway to continue R&D without immediate external dilution. 3. Low overhead structure with no long-term liabilities or fixed asset burdens typical of mature manufacturing firms.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.